Abstract:Introduction: The depressive disorders are among the most frequent disorders in the general population. Various validated treatments exist but, according to international psychiatric epidemiologic surveys, only a minority of currently depressed people seek and receive treatment. To date, in France, few national studies have investigated these problems. Objectives: By using the data of the national French survey: "Santé mentale en population générale (SMPG)": 1) to estimate the prevalence of use of care services by depressed people in the general population, 2) to evaluate the proportion of depressive subjects who have received drug and/or psychological treatments, 3) to identify the demographic and clinical factors and representations associated with use. Method: SMPG was a transversal survey carried out by the WHO national collaborative center (CCOMS) and the Direction of the statistics of the ministry for Health (DREES). A representative sample of 36 105 non-institutionalised French individuals aged 18 or over was interviewed. Three main questionnaires was used: the Mini International Neuropsychiatric Interview (MINI) questionnaire was used to assess several mental disorders according to the ICD-10 classification, a questionnaire on the representations of the mental disease and the treatments, and a questionnaire on use of care services and treatments received. Results: - 71.9% of depressed people sought or received a treatment and 47.1% stated claimed to be treated for depression. About 20% of people classified as having a recurrent or chronic depressive disorder have never used health care services for mental health. Only 53.4% of subjects having a mild or moderate Major Depressive Episode (MDE) already received a treatment: 42.1% had taken psychotropic drugs only, 3.2% had psychotherapy only, 8.1% had both, and 25.6% had taken antidepressants among the subjects treated by psychotropic drugs; 24% of subjects classified as having a recurrent or chronic depressive disorder have never received a treatment and about 3/4 of them have never received a minimal adequate treatment. Use of services by depressed people was associated with sociodemographic factors, the severity of the disorder and several representations. Conclusion: - The SMPG survey confirms the international finding concerning the treatment of depressed people. Several problems were pointed out: an important part of depressed people had never taken any treatment, less than half claimed they were stated to be treated for depression, a minority received a psychotherapy, and very few had a minimal adequate treatment. In France, more psychiatric epidemiologic surveys are needed to confirm and specify these findings.

Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France

Agomelatine for depression: expanding the horizons?

Focus on agomelatine

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?

The preclinical discovery and development of agomelatine for the treatment of depression

[Melatonergic antidepressant agomelatine: augmentation of antipsychotic drugs in treatment of post-schizophrenic depression]

Pharmacological actions and clinical efficacy of agomelatine

Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study

Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine

Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case–Control Study Using Automated Health Data Sources

Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine

Systematic review and network meta-analysis of agomelatine for the treatment of generalized anxiety disorder in adult patients

The use of agomelatine in the reduction of anhedonia and sleep disorders in the course of depression

[Use of health services and treatments for major depressive episode in France]

Agomelatine enhances the therapeutic effect of venlafaxine on depression and improves the levels of S100B and GFAP.

Open Trial Study Treatment with Agomelatine in Elderly Patients with Major Depressive Disorder with Hyponatremia Due to SSRI Use

Efficacy and safety of agomelatine versus SSRIs/SNRIs for post-stroke depression: a systematic review and meta-analysis of randomized controlled trials

General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry

General Practitioners' Choices and Their Determinants When Starting Treatment for Major Depression: A Cross Sectional, Randomized Case-Vignette Survey

Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders